Publication date: Aug 28, 2019
Determine if patient-specific factors modulate absolute lymphocyte count (ALC), neutrophil count (ANC), and/or Neutrophile-lymphocyte ratio (NLR) in Dimethyl Fumarate (DMF) treated patients.
A retrospective study of patients who initiated DMF between 2013-2018. A multicenter study of two MS clinics: Charlottesville, VA (UVA) and Dallas, TX (DaVA).
103 patients (67-UVA, 36-DaVA) met eligibility. At baseline, the DaVa population was younger (mean+/-sd: 38.6+/-9.0 vs 42.2+/-12.5, p 0.152) and had a higher proportion of males (61% vs. 35%), consistent with a veteran cohort. Pre-treatment, all other laboratory parameters were similar between the two groups. On treatment there was a 30% lowering of mean ALC, with 3% having grade-3 lymphopenia (ALC
Patient-specific factors, specifically-age, sex, and serum blood glucose, modulate leukocyte response and ratios in DMF treated MS patients. Age appears to be a relevant predictor of lymphopenia and should be a factor in treatment decision making. Neutropenia, independent of lymphopenia, can occur and males may be at increased risk. High sBG may impact leukocyte count and ratios in MS patients and merits further study, particularly in patients with diabetes. NLR is abnormal in MS and increased with DMF-treatment, the clinical implications of this will require further study.
Open Access PDF
Goldman, M.D., Dwyer, L., Coleman, R., Sohn, M.W., and Stuve, O. Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients. 20191. 2019 PLoS One (15):2.
|disease||MESH||Type 1 diabetes|
|drug||DRUGBANK||Antithymocyte immunoglobulin (rabbit)|
|disease||MESH||progressive multifocal leukoencephalopathy|
|drug||DRUGBANK||Dextrose unspecified form|